Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun;9(6):579-94.
doi: 10.1517/17460441.2014.908180. Epub 2014 Apr 7.

Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal

Rebecca L Ashare  1 , Heath D Schmidt
Affiliations
Review

Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal

Rebecca L Ashare et al. Expert Opin Drug Discov. 2014 Jun.

Abstract

Introduction: Current FDA-approved smoking cessation pharmacotherapies have limited efficacy and are associated with high rates of relapse. Therefore, there is a clear need to develop novel antismoking medications. Nicotine withdrawal is associated with cognitive impairments that predict smoking relapse. It has been proposed that these cognitive deficits are a hallmark of nicotine withdrawal that could be targeted in order to prevent smoking relapse. Thus, pharmacotherapies that increase cognitive performance during nicotine withdrawal may represent potential smoking cessation agents.

Areas covered: The authors review the clinical literature demonstrating that nicotine withdrawal is associated with deficits in working memory, attention and response inhibition. They then briefly summarize different classes of compounds and strategies to increase cognitive performance during nicotine withdrawal. Particular emphasis has been placed on translational research in order to highlight areas for which there is strong rationale for pilot clinical trials of potential smoking cessation medications.

Expert opinion: There is emerging evidence that supports deficits in cognitive function as a plausible nicotine withdrawal phenotype. The authors furthermore believe that the translational paradigms presented here may represent efficient and valid means for the evaluation of cognitive-enhancing medications as possible treatments for nicotine dependence.

Keywords: cognition; nicotine; reinstatement; relapse; self-administration; smoking; tobacco; withdrawal.

PubMed Disclaimer

References

    1. Rostron B. Smoking-attributable mortality by cause in the United States: revising the CDC’s data and estimates. Nicotine Tob Res. 2013;15(1):238–46. - PubMed
    1. (CDCP) CfDCaP Quitting smoking among adults–United States, 2001-2010. MMWR Morb Mortal Wkly Rep. 2011;60(44):1513–19. - PubMed
    1. Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA. 2014;311(2):193–4. - PubMed
    1. Garvey AJ, Bliss RE, Hitchcock JL, et al. Predictors of smoking relapse among self-quitters: a report from the Normative Aging Study. Addict Behav. 1992;17(4):367–77. - PubMed
    1. Hughes JR. Tobacco withdrawal in self-quitters. J Consult Clin Psychol. 1992;60(5):689–97. - PubMed

Publication types

MeSH terms

LinkOut - more resources